4-(chloromethyl)-2-(4-fluoro-3-methylphenyl)oxazole | 1030623-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(chloromethyl)-2-(4-fluoro-3-methylphenyl)oxazole
• 英文别名: 4-(chloromethyl)-2-(4-fluoro-3-methylphenyl)-1,3-oxazole
• CAS: 1030623-76-7
• 化学式: C₁₁H₉ClFNO
• 分子量: 225.65
• InChiKey: PREXEIDSIGWUFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(chloromethyl)-2-(4-fluoro-3-methylphenyl)oxazole 在 4-二甲氨基吡啶 、 potassium hydroxide 、 N,N'-二异丙基碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 N-[3-[(3S,5R)-3,5-dimethylpiperidin-1-yl]propyl]-1-[[2-(4-fluoro-3-methylphenyl)-1,3-oxazol-4-yl]methyl]piperidine-4-carboxamide
  参考文献：
  名称：

  Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

  摘要：

  Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of Iii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

  DOI：

  10.1021/acs.jmedchem.7b00561
• 作为产物：
  描述：

  4-氟-3-甲基苯甲酰胺 、 1,3-二氯丙酮 在 硫酸 作用下， 反应 48.25h， 生成 4-(chloromethyl)-2-(4-fluoro-3-methylphenyl)oxazole
  参考文献：
  名称：

  CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF

  摘要：

  本申请涉及新型的4-环烷基和4-杂环烷基-3,5-二氰基-2-硫代吡啶衍生物，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制备治疗和/或预防疾病的药物的用途，优选用于治疗和/或预防高血压和其他心血管疾病。

  公开号：

  US20100022544A1

文献信息

• SUBSTITUTED ARYLOXAZOLES AND THEIR USE
  申请人：Nell Peter

  公开号：US20110130377A1

  公开（公告）日：2011-06-02

  The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

  本申请涉及新型取代芳氧唑衍生物，其生产方法，用于治疗和/或预防疾病的用途，以及用于生产用于治疗和/或预防疾病的药物的用途，优选用于治疗和/或预防心血管和代谢紊乱。
• Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof
  申请人：Bayer Intellectual Property GmbH

  公开号：US08304412B2

  公开（公告）日：2012-11-06

  The present application relates to novel 4-cycloalkyl- and 4-heterocycloalkyl-3,5-dicyano-2-thio-pyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.

  本申请涉及新型4-环烷基和4-杂环烷基-3,5-二氰基-2-硫吡啶衍生物，其制备过程，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，优选用于治疗和/或预防高血压和其他心血管疾病。
• Substituted aryloxazoles and their use
  申请人：Nell Peter

  公开号：US08440700B2

  公开（公告）日：2013-05-14

  The present application relates to novel substituted aryloxazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

  本申请涉及新型取代芳基噁唑衍生物，以及其制备方法，用于治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，优选用于治疗和/或预防心血管和代谢性疾病。
• CYCLISCH SUBSTITUIERTE 3,5-DICYANO-2-THIOPYRIDINE UND IHRE VERWENDUNG
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2099788A1

  公开（公告）日：2009-09-16
• SUBSTITUIERTE ARYLOXAZOLE UND IHRE VERWENDUNG
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2185550A1

  公开（公告）日：2010-05-19